NMN study #2
The Japanese Keio University had a research team that investigated and showed, for the first time, that NMN, an anti-aging intervention compound, is safe to be administered to healthy humans. This research team was led by Prof. Kazuo Tsubota of the Department of Ophthalmology, Prof. Hiroshi Itoh of the Department of Internal Medicine, Prof. Hideyuki Okano of the Department of Physiology, and Prof. Masato Yasui of the Department of Pharmacology, along with a collaboration of Washington University School of Medicine in St. Louis.
This is because, in 2015, both universities agreed to conduct joint investigations on subjects such as longevity. The study establishes that “Recent studies in animal models have shown that the administration of NMN increases the amount of nicotinamide adenine dinucleotide (NAD+) in various organs and improves age-associated functional decline and disease conditions. However, the safety of NMN in humans has remained unclear.
Since 2016, the research team has conducted a clinical trial study to investigate the safety of single administration of NMN in ten healthy men and has confirmed that it can be safely administered and that it is effectively metabolized in the body. This study is expected to inform future treatment of age-associated diseases.”
For this study, 10 healthy men aged 40 to 60 years were administered a single dose of 100, 250, or 500 mg of NMN orally. This oral administrations of NMN didn’t produce remarkable changes in blood pressure or in heart rate. Urine and blood tests, used for analyzing kidney and liver function, didn’t exceed the normal levels. Also, these single doses didn’t affect sleep quality nor did they change eye functions.
During the measurement of the number of plasma metabolites produced from NMN, the team found said plasma metabolites had increased accordingly to the dosage. From this, it was concluded that orally administered NMN can be metabolized in the human body and is safe to be used at single doses up to 500mg.
Past studies investigated treatments for the increase of NAD+ tissue in order to prevent age-related diseases, but, currently, one of the leading candidates for the stimulation of sirtuin1 enzymes, which has a critical role in longevity control in mammalians, is NMN. For the first time, because of this clinical study, it has been shown that NMN is safe for humans and that further development of research about the application of NMN for the treatment of age-related diseases can be expected.
The team is also planning a study on the long-term administration of NMN in healthy subjects.
https://www.keio.ac.jp/en/press-releases/files/2020/2/25/200225-1.pdf